Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.

Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.

Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.

Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.

Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.

Dr. Elena Christofides on why patients who don't respond to diabetes medications deserve a diagnostic workup — not a non-adherence label.

Dr. Elena Christofides on why treatment failure in diabetes should trigger a cortisol screen — not an assumption of non-adherence.

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction.